[go: up one dir, main page]

PE20191653A1 - Metodos para tratar carcinomas uroteliales del tracto superior - Google Patents

Metodos para tratar carcinomas uroteliales del tracto superior

Info

Publication number
PE20191653A1
PE20191653A1 PE2019000993A PE2019000993A PE20191653A1 PE 20191653 A1 PE20191653 A1 PE 20191653A1 PE 2019000993 A PE2019000993 A PE 2019000993A PE 2019000993 A PE2019000993 A PE 2019000993A PE 20191653 A1 PE20191653 A1 PE 20191653A1
Authority
PE
Peru
Prior art keywords
ureter
utuc
chemotherapeutic agent
methods
catheter
Prior art date
Application number
PE2019000993A
Other languages
English (en)
Inventor
Guru V Betageri
Natarajan Venkatesan
Michael G Oefelein
Original Assignee
Univ Western Health Sciences
Tesorx Pharma Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Western Health Sciences, Tesorx Pharma Llc filed Critical Univ Western Health Sciences
Publication of PE20191653A1 publication Critical patent/PE20191653A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/10—Balloon catheters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/10—Balloon catheters
    • A61M2025/1043—Balloon catheters with special features or adapted for special applications
    • A61M2025/105—Balloon catheters with special features or adapted for special applications having a balloon suitable for drug delivery, e.g. by using holes for delivery, drug coating or membranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M25/00—Catheters; Hollow probes
    • A61M25/10—Balloon catheters
    • A61M2025/1043—Balloon catheters with special features or adapted for special applications
    • A61M2025/1052—Balloon catheters with special features or adapted for special applications for temporarily occluding a vessel for isolating a sector
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2210/00—Anatomical parts of the body
    • A61M2210/10—Trunk
    • A61M2210/1078—Urinary tract
    • A61M2210/1089—Urethra

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dispersion Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Materials For Medical Uses (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Referido a un metodo para administrar de manera local un agente quimioterapeutico a un carcinoma urotelial de tracto superior (UTUC), que comprende: (a) colocar un cateter con balon que tiene un canal de trabajo, a traves de acceso ureteral retrogrado o anterogrado en el ureter y/o pelvis renal; (b) inflar el balon del cateter de mod que el ureter quede temporalmente obstruido; (c) instilar una formulacion liposomal liquida que comprende un agente quimioterapeutico dentro del canal de trabajo del cateter; y (d) permitir que la formulacion liposomal instilada permanezca en el ureter y/o pelvis renal durante un tiempo suficiente para permitir que al menos una parte de la formulacion liposomal se adhiera a la pared urotelial. En donde el agente quimioterapeutico es taxano o cisplatino. Y se usa en terapia adyuvante con respecto a otros metodos para tratar UTUC, tales como extirpacion o ablacion ureteroscopica del tumor UTUC.
PE2019000993A 2016-11-11 2017-11-10 Metodos para tratar carcinomas uroteliales del tracto superior PE20191653A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662421055P 2016-11-11 2016-11-11
PCT/US2017/061047 WO2018089759A1 (en) 2016-11-11 2017-11-10 Methods of treating upper tract urothelial carcinomas

Publications (1)

Publication Number Publication Date
PE20191653A1 true PE20191653A1 (es) 2019-11-07

Family

ID=62109985

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2019000993A PE20191653A1 (es) 2016-11-11 2017-11-10 Metodos para tratar carcinomas uroteliales del tracto superior

Country Status (16)

Country Link
US (1) US20190343763A1 (es)
EP (1) EP3538074B1 (es)
JP (1) JP7096553B2 (es)
KR (1) KR20190084284A (es)
CN (1) CN110167533A (es)
AU (1) AU2017358049B2 (es)
BR (1) BR112019009616A2 (es)
CA (1) CA3043620A1 (es)
CL (1) CL2019001262A1 (es)
CO (1) CO2019005881A2 (es)
CR (1) CR20190274A (es)
EA (1) EA201991143A1 (es)
MX (1) MX390168B (es)
NZ (1) NZ753214A (es)
PE (1) PE20191653A1 (es)
WO (1) WO2018089759A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20181445A1 (es) * 2016-01-07 2018-09-12 Univ Western Health Sciences Formulaciones para el tratamiento del cancer de vejiga
GB201900389D0 (en) 2019-01-11 2019-02-27 Queens Univ Of Belfast Solvent and water-free lipid-based nanoparticles and their methods of manufacture
KR20220054318A (ko) * 2019-08-09 2022-05-02 테소륵스 파마, 엘엘씨 프로리포솜성 테스토스테론 운데카노에이트 제형

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6759058B1 (en) 2001-04-25 2004-07-06 Western Center For Drug Development College Of Pharmacy Western University Of Health Sciences Enteric-coated proliposomal formulations for poorly water soluble drugs
AU2002334595B2 (en) 2001-09-24 2007-03-01 Tosk, Inc. Reduced toxicity cisplatin formulations and methods for using the same
PT2286794T (pt) 2003-10-15 2016-07-13 Syncore Biotechnology Co Ltd Uso de lipossomas catiónicos contendo placlitaxel
US20090171241A1 (en) 2006-03-03 2009-07-02 Garcia Maurice M System and method for urinary tract cell collection, diagnosis, and chemotherapy
US20100034874A1 (en) 2006-12-08 2010-02-11 Katayama Chemical Industries Co., Ltd. Liposome encapsulating ammine-platinum complex at high concentration, and method for production of the liposome
WO2008114274A1 (en) * 2007-03-19 2008-09-25 Fresenius Kabi Onclology Ltd. Proliposomal and liposomal compositions
CN101322689B (zh) * 2007-06-11 2012-10-24 江苏先声药物研究有限公司 一种多西他赛长循环脂质体及其冻干粉针的制备方法
EA201791738A1 (ru) * 2012-05-09 2018-03-30 Вестерн Юниверсити Оф Хелт Сайенсиз Пролипосомальные композиции тестостерона
WO2016172343A1 (en) 2015-04-24 2016-10-27 Urotronic, Inc. Drug coated balloon catheters for nonvascular strictures
US20140172118A1 (en) 2012-12-19 2014-06-19 Cook Medical Technologies Llc Bioactive Compositions, Bioactive Eluting Devices and Methods of Use Thereof
US20160175559A1 (en) * 2014-12-23 2016-06-23 Cook Medical Technologies Llc Medical Devices for Delivery and Retention of Bioactive Agents
WO2016134066A1 (en) * 2015-02-17 2016-08-25 Mallinckrodt Llc Modified docetaxel liposome formulations and uses thereof
EP4193939B1 (en) 2015-03-26 2025-02-26 Vensica Medical Ltd. Ultrasonic urinary bladder drug delivery
JP6249987B2 (ja) * 2015-05-13 2017-12-20 ルトニックス，インコーポレーテッド 医療用具のための薬物放出コーティング
PE20181445A1 (es) 2016-01-07 2018-09-12 Univ Western Health Sciences Formulaciones para el tratamiento del cancer de vejiga

Also Published As

Publication number Publication date
EP3538074B1 (en) 2023-07-26
AU2017358049B2 (en) 2023-11-09
NZ753214A (en) 2022-02-25
CO2019005881A2 (es) 2019-08-30
CN110167533A (zh) 2019-08-23
CR20190274A (es) 2019-07-29
CA3043620A1 (en) 2018-05-17
BR112019009616A2 (pt) 2019-08-13
JP2019534305A (ja) 2019-11-28
MX390168B (es) 2025-03-20
WO2018089759A1 (en) 2018-05-17
CL2019001262A1 (es) 2019-07-26
KR20190084284A (ko) 2019-07-16
US20190343763A1 (en) 2019-11-14
EP3538074A1 (en) 2019-09-18
MX2019005185A (es) 2019-07-01
JP7096553B2 (ja) 2022-07-06
AU2017358049A1 (en) 2019-05-30
EP3538074A4 (en) 2020-06-24
EA201991143A1 (ru) 2019-10-31

Similar Documents

Publication Publication Date Title
WO2015186003A3 (en) Methods and devices for treating pulmonary edema
WO2016015001A3 (en) Combination fluid instillation and negative pressure dressing
CL2020000106A1 (es) Sondas ureterales y vesicales y métodos para inducir presión negativa para aumentar la perfusión renal. (divisional solicitud 201800153)
PE20191653A1 (es) Metodos para tratar carcinomas uroteliales del tracto superior
WO2016040579A8 (en) Perfusion catheters and related methods
BRPI0919884B8 (pt) cateter de perfusão de oclusão
CO2017007662A2 (es) Terapias de combinación para el tratamiento de cánceres
MX2016010532A (es) Sistemas y metodos para cicatrizacion de tejido.
WO2017160781A3 (en) Devices for delivering a chemical denervation agent and methods of use
MX384437B (es) Sistemas de tratamiento criogénico.
MX2016016069A (es) Dispositivo de administración de agente terapeutico con lumen convergente.
MX2018001375A (es) Metodo para suministro de liquido para un sistema de rf enfriado.
MX373231B (es) Agente anticancerigeno.
AR098688A1 (es) Métodos para minimizar el sobredesplazamiento de apuntalante en tratamientos de fracturas
MX2020011581A (es) Catéter de globo.
WO2014150539A3 (en) System and method for multiple direction flexible inline canister
WO2019051274A3 (en) DEVICES FOR THE TREATMENT OF BRONCHOPULMONARY TUMORS
CA3018145C (en) TREATMENT METHOD FOR TRIPLE-NEGATIVE BREAST CANCER
DOP2023000155A (es) Tratamiento y terapia de mantenimiento para el cáncer de vejiga con gemcitabina
MX2021014524A (es) Metodos para tratar canceres del sistema urinario.
MX2018008196A (es) Tratamiento para cancer de mama usando una combinacion de una formulacion liposomal cationica de taxano, una formulacion no liposomal de taxano y un agente activo adicional.
MX2021002884A (es) Terapia de combinacion para el tratamiento de cancer de prostata.
HK1251866A1 (zh) 用於剔除身体血管的方法和装置
CN204352357U (zh) 一种三腔胸腔闭式引流管
Ohlmann et al. Comment re: Sternberg CN, Skoneczna I, Kerst JM, et al. Immediate Versus Deferred Chemotherapy After Radical Cystectomy in Patients with pT3-pT4 or N+ M0 Urothelial Carcinoma of the Bladder (EORTC 30994): An Intergroup, Open-label, Randomised Phase 3 Trial. Lancet Oncol 2015; 16: 76-86